'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial

Ann Oncol. 2017 Oct 1;28(10):2327-2330. doi: 10.1093/annonc/mdx410.

Authors

M R Spears¹, N D James², M R Sydes³

Affiliations

¹ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London.
² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
³ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London. Electronic address: m.sydes@ucl.ac.uk.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Androstenes / administration & dosage
Antineoplastic Agents / administration & dosage
Data Interpretation, Statistical
Docetaxel
Humans
Male
Prostatic Neoplasms* / drug therapy
Randomized Controlled Trials as Topic* / methods
Taxoids / administration & dosage

Substances

abiraterone
Androstenes
Antineoplastic Agents
Docetaxel
Taxoids

Grants and funding